Work

A phase II multicenter, randomized, placebo-controlled, double-blind study of CC-486 plus pembrolizumab (pembro) vs pembro plus placebo (PBO) in previously treated patients (pts) with locally advanced/metastatic non-small cell lung cancer (NSCLC).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.tps9107

Authors: Benjamin Philip Levy, Giuseppe Giaccone, Benjamin Besse, Damir Begic, Xiaoling Wu, Abderrahim Fandi, Luis Paz-Ares

Institutions: Mount Sinai Health System, Georgetown University, Institut Gustave Roussy, Fondation Gustave Roussy, Celgene (United States), Hospital Universitario Virgen del Rocío

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891095353

Cites:

Cited by: 5

Related to: 10